157 related articles for article (PubMed ID: 17076521)
1. Effect of fondaparinux on coagulation assays: results of College of American Pathologists proficiency testing.
Smogorzewska A; Brandt JT; Chandler WL; Cunningham MT; Hayes TE; Olson JD; Kottke-Marchant K; Van Cott EM
Arch Pathol Lab Med; 2006 Nov; 130(11):1605-11. PubMed ID: 17076521
[TBL] [Abstract][Full Text] [Related]
2. Laboratory-monitored fondaparinux and coagulation activity in association with total hip replacement.
Virtanen L; Salmela B; Leinonen J; Lemponen M; Huhtala J; Joutsi-Korhonen L; Lassila R
Blood Coagul Fibrinolysis; 2014 Sep; 25(6):597-603. PubMed ID: 24732174
[TBL] [Abstract][Full Text] [Related]
3. Monitoring fondaparinux with the Sonoclot.
Nilsson CU; Engström M
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):619-22. PubMed ID: 17890948
[TBL] [Abstract][Full Text] [Related]
4. In vitro comparison of the effect of fondaparinux and enoxaparin on whole blood tissue factor-triggered thromboelastography profile.
Gerotziafas GT; Chakroun T; Samama MM; Elalamy I
Thromb Haemost; 2004 Dec; 92(6):1296-302. PubMed ID: 15583737
[TBL] [Abstract][Full Text] [Related]
5. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
Samama MM; Martinoli JL; LeFlem L; Guinet C; Plu-Bureau G; Depasse F; Perzborn E
Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma.
Gerotziafas GT; Depasse F; Chakroun T; Van Dreden P; Samama MM; Elalamy I
Blood Coagul Fibrinolysis; 2004 Mar; 15(2):149-56. PubMed ID: 15091002
[TBL] [Abstract][Full Text] [Related]
7. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux.
Samama MM; Mendell J; Guinet C; Le Flem L; Kunitada S
Thromb Res; 2012 Apr; 129(4):e77-82. PubMed ID: 21851967
[TBL] [Abstract][Full Text] [Related]
8. Effects of pentasaccharide (fondaparinux) and direct thrombin inhibitors on coagulation testing.
Gosselin RC; King JH; Janatpur KA; Dager WH; Larkin EC; Owings JT
Arch Pathol Lab Med; 2004 Oct; 128(10):1142-5. PubMed ID: 15387708
[TBL] [Abstract][Full Text] [Related]
9. Determination of antithrombin-dependent factor Xa inhibitors by prothrombin-induced clotting time.
Harenberg J; Giese C; Hagedorn A; Traeger I; Fenyvesi T
Semin Thromb Hemost; 2007 Jul; 33(5):503-7. PubMed ID: 17629847
[TBL] [Abstract][Full Text] [Related]
10. Development and clinical evaluation of two chromogenic substrate methods for monitoring fondaparinux sodium.
Klaeffling C; Piechottka G; Daemgen-von Brevern G; Mosch G; Mani H; Luxembourg B; Lindhoff-Last E
Ther Drug Monit; 2006 Jun; 28(3):375-81. PubMed ID: 16778722
[TBL] [Abstract][Full Text] [Related]
11. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers.
Bijsterveld NR; Moons AH; Boekholdt SM; van Aken BE; Fennema H; Peters RJ; Meijers JC; Büller HR; Levi M
Circulation; 2002 Nov; 106(20):2550-4. PubMed ID: 12427650
[TBL] [Abstract][Full Text] [Related]
12. Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays.
Hillarp A; Strandberg K; Baghaei F; Fagerberg Blixter I; Gustafsson KM; Lindahl TL
Scand J Clin Lab Invest; 2018; 78(7-8):575-583. PubMed ID: 30278787
[TBL] [Abstract][Full Text] [Related]
13. Impact of antithrombin deficiency on efficacy of edoxaban and antithrombin-dependent anticoagulants, fondaparinux, enoxaparin, and heparin.
Fukuda T; Kamisato C; Honda Y; Matsushita T; Kojima T; Furugohri T; Morishima Y; Shibano T
Thromb Res; 2013 Jun; 131(6):540-6. PubMed ID: 23673387
[TBL] [Abstract][Full Text] [Related]
14. Favorable coagulation profile with fondaparinux after hip surgery in elderly patients.
Kudrnová Z; Kvasnička J; Kudrna K; Mazoch J; Malíková I; Zenáhlíková Z; Sudrová M; Brzežková R
Int J Hematol; 2009 Nov; 90(4):476-482. PubMed ID: 19838769
[TBL] [Abstract][Full Text] [Related]
15. Activated partial thromboplastin time and anti-xa measurements in heparin monitoring: biochemical basis for discordance.
Takemoto CM; Streiff MB; Shermock KM; Kraus PS; Chen J; Jani J; Kickler T
Am J Clin Pathol; 2013 Apr; 139(4):450-6. PubMed ID: 23525615
[TBL] [Abstract][Full Text] [Related]
16. Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey.
Van Blerk M; Bailleul E; Chatelain B; Demulder A; Devreese K; Douxfils J; Jochmans K; Mullier F; Wijns W; Soumali MR; Coucke W; Vernelen K; Van de Walle P
Thromb Haemost; 2015 Jan; 113(1):154-64. PubMed ID: 25231101
[TBL] [Abstract][Full Text] [Related]
17. Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood.
Gerotziafas GT; Depasse F; Chakroun T; Samama MM; Elalamy I
Thromb Haemost; 2004 Mar; 91(3):531-7. PubMed ID: 14983229
[TBL] [Abstract][Full Text] [Related]
18. Multianalyte Determination of NOACs Using LC-MS/MS and Comparison with Functional Coagulation Assays.
Slavik L; Lukes J; Friedecky D; Zhanelova M; Nemcova M; Ulehlova J; Prochazkova J; Hlusi A; Palova M; Vaclavik J
Clin Lab; 2018 Oct; 64(10):1611-1621. PubMed ID: 30336535
[TBL] [Abstract][Full Text] [Related]
19. The reduced anticoagulant effect of fondaparinux at low antithrombin levels.
Dempfle CE; Eichner J; Suvajac N; Ahmad-Nejad P; Neumaier M; Borggrefe M
Anesth Analg; 2009 Sep; 109(3):712-6. PubMed ID: 19690236
[TBL] [Abstract][Full Text] [Related]
20. Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis.
Potze W; Arshad F; Adelmeijer J; Blokzijl H; van den Berg AP; Porte RJ; Lisman T
Br J Haematol; 2013 Dec; 163(5):666-73. PubMed ID: 24219333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
